Madrigal Pharmaceuticals Inc (MDGL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Madrigal Pharmaceuticals Inc (MDGL) has a cash flow conversion efficiency ratio of -0.221x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-133.46 Million) by net assets ($602.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Madrigal Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Madrigal Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Madrigal Pharmaceuticals Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Madrigal Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Madrigal Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Meritz Financi
KO:138040
|
-0.176x |
|
Corebridge Financial Inc.
NYSE:CRBG
|
-0.001x |
|
GAIL (India) Limited
NSE:GAIL
|
0.065x |
|
China Shipbuilding Industry Group Power Co Ltd
SHG:600482
|
0.044x |
|
Pentair PLC
NYSE:PNR
|
-0.018x |
|
Alchip Technologies Ltd
TW:3661
|
-0.025x |
|
McCormick & Company Incorporated
NYSE:MKC
|
0.094x |
|
American Homes 4 Rent
NYSE:AMH
|
0.028x |
Annual Cash Flow Conversion Efficiency for Madrigal Pharmaceuticals Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of Madrigal Pharmaceuticals Inc from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see MDGL stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $602.69 Million | $-189.55 Million | -0.315x | +47.92% |
| 2024-12-31 | $754.38 Million | $-455.57 Million | -0.604x | +24.50% |
| 2023-12-31 | $405.33 Million | $-324.23 Million | -0.800x | +29.78% |
| 2022-12-31 | $197.39 Million | $-224.86 Million | -1.139x | -21.47% |
| 2021-12-31 | $196.11 Million | $-183.92 Million | -0.938x | -42.84% |
| 2020-12-31 | $239.97 Million | $-157.56 Million | -0.657x | -557.10% |
| 2019-12-31 | $416.56 Million | $-41.62 Million | -0.100x | -86.86% |
| 2018-12-31 | $476.98 Million | $-25.51 Million | -0.053x | +56.33% |
| 2017-12-31 | $182.26 Million | $-22.32 Million | -0.122x | +74.68% |
| 2016-12-31 | $36.41 Million | $-17.61 Million | -0.484x | +65.88% |
| 2015-12-31 | $50.41 Million | $-71.44 Million | -1.417x | -16.97% |
| 2014-12-31 | $65.14 Million | $-78.92 Million | -1.212x | +23.16% |
| 2013-12-31 | $49.09 Million | $-77.41 Million | -1.577x | -118.66% |
| 2012-12-31 | $75.07 Million | $-54.13 Million | -0.721x | +77.47% |
| 2011-12-31 | $14.77 Million | $-47.30 Million | -3.202x | -96.78% |
| 2010-12-31 | $23.48 Million | $-38.20 Million | -1.627x | -51.17% |
| 2009-12-31 | $24.91 Million | $-26.81 Million | -1.076x | -266.77% |
| 2008-12-31 | $-58.79 Million | $-37.94 Million | 0.645x | -40.98% |
| 2007-12-31 | $24.90 Million | $27.22 Million | 1.093x | -96.39% |
| 2006-12-31 | $-1.75 Million | $-52.98 Million | 30.329x | +2671.96% |
| 2005-12-31 | $52.48 Million | $-61.88 Million | -1.179x | -311.59% |
| 2004-12-31 | $117.96 Million | $-33.80 Million | -0.287x | +6.70% |
| 2003-12-31 | $76.89 Million | $-23.61 Million | -0.307x | -- |
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.